176 related articles for article (PubMed ID: 36358658)
1. Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis.
Rungjirajittranon T; Siriwannangkul T; Kungwankiattichai S; Leelakanok N; Rotchanapanya W; Vittayawacharin P; Mekrakseree B; Kulchutisin K; Owattanapanich W
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358658
[TBL] [Abstract][Full Text] [Related]
2. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.
Quesada AE; Montalban-Bravo G; Luthra R; Patel KP; Sasaki K; Bueso-Ramos CE; Khoury JD; Routbort MJ; Bassett R; Hidalgo-Lopez JE; Zhao C; Lin P; Loghavi S; Ok CY; Kadia T; DiNardo CD; Kantarjian H; Garcia-Manero G; Kanagal-Shamanna R
Mod Pathol; 2020 Sep; 33(9):1678-1689. PubMed ID: 32238878
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutated
Nguyen L; Zhang X; Roberts E; Yun S; McGraw K; Abraham I; Song J; Braswell D; Qin D; Sallman DA; Lancet JE; List AF; Moscinski LC; Padron E; Zhang L
Leuk Lymphoma; 2020 Jun; 61(6):1395-1405. PubMed ID: 32091281
[TBL] [Abstract][Full Text] [Related]
5. Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study.
Wan CL; Huang YH; Huang SM; Xu YL; Tan KW; Yan-Qiu ; Shen XD; Ge SS; Cao HY; Li YY; Liu SB; Qi JJ; Dai HP; Xue SL
Leuk Res; 2024 Apr; 139():107483. PubMed ID: 38493755
[TBL] [Abstract][Full Text] [Related]
6. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
7. NRAS
Pan L; Liang F; Chen X; Hao Z; Muyey DM; Chen X; Wang H
Ann Clin Lab Sci; 2023 May; 53(3):389-397. PubMed ID: 37437942
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia.
Chen X; Zhu H; Qiao C; Zhao S; Liu L; Wang Y; Jin H; Qian S; Wu Y
Hematology; 2021 Dec; 26(1):111-122. PubMed ID: 33491606
[TBL] [Abstract][Full Text] [Related]
9. Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
Han H; Yao Y; Wang H; Zhou M; Zhang Z; Xu X; Qi J; Liu Y; Wu D; Han Y
Cancer; 2023 Jan; 129(2):245-254. PubMed ID: 36370049
[TBL] [Abstract][Full Text] [Related]
10. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
[TBL] [Abstract][Full Text] [Related]
11. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
Waidhauser J; Labopin M; Esteve J; Kröger N; Cornelissen J; Gedde-Dahl T; Van Gorkom G; Finke J; Rovira M; Schaap N; Petersen E; Beelen D; Bunjes D; Savani B; Schmid C; Nagler A; Mohty M;
Bone Marrow Transplant; 2021 Oct; 56(10):2445-2453. PubMed ID: 34059800
[TBL] [Abstract][Full Text] [Related]
13. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Mutation Profile in Acute Myeloid Leukemia Patients with
Qin W; Chen X; Shen HJ; Wang Z; Cai X; Jiang N; Hua H
Turk J Haematol; 2022 Jun; 39(2):84-93. PubMed ID: 35445594
[TBL] [Abstract][Full Text] [Related]
15. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome.
Krauth MT; Eder C; Alpermann T; Bacher U; Nadarajah N; Kern W; Haferlach C; Haferlach T; Schnittger S
Leukemia; 2014 Jul; 28(7):1449-58. PubMed ID: 24402164
[TBL] [Abstract][Full Text] [Related]
16. Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
Stengel A; Kern W; Meggendorfer M; Nadarajah N; Perglerovà K; Haferlach T; Haferlach C
Leukemia; 2018 Feb; 32(2):295-302. PubMed ID: 28751771
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.
Röllig C; Bornhäuser M; Kramer M; Thiede C; Ho AD; Krämer A; Schäfer-Eckart K; Wandt H; Hänel M; Einsele H; Aulitzky WE; Schmitz N; Berdel WE; Stelljes M; Müller-Tidow C; Krug U; Platzbecker U; Wermke M; Baldus CD; Krause SW; Stölzel F; von Bonin M; Schaich M; Serve H; Schetelig J; Ehninger G
J Clin Oncol; 2015 Feb; 33(5):403-10. PubMed ID: 25547501
[TBL] [Abstract][Full Text] [Related]
18. Chemogenomic Landscape of
Simon L; Lavallée VP; Bordeleau ME; Krosl J; Baccelli I; Boucher G; Lehnertz B; Chagraoui J; MacRae T; Ruel R; Chantigny Y; Lemieux S; Marinier A; Hébert J; Sauvageau G
Clin Cancer Res; 2017 Nov; 23(22):6969-6981. PubMed ID: 28855357
[No Abstract] [Full Text] [Related]
19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
20. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML.
Schoch C; Kern W; Schnittger S; Hiddemann W; Haferlach T
Leukemia; 2004 Jan; 18(1):120-5. PubMed ID: 14586477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
